164 related articles for article (PubMed ID: 37669312)
1. Anti-CD20 should be the first-line treatment in high-risk membranous nephropathy.
Zand L; Fervenza FC
Clin Kidney J; 2023 Sep; 16(9):1420-1425. PubMed ID: 37669312
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of long-term repeated rituximab treatment in refractory phospholipase A2 receptor-antibody-related membranous nephropathy.
Zhang L; Chen M; Le W; Zhang M; Tu Y; Zuo K; Chen D; Wu Y; Li S; Zeng C; Cheng Z; Xie H
Immunotherapy; 2022 Oct; 14(15):1237-1244. PubMed ID: 36097696
[TBL] [Abstract][Full Text] [Related]
3. Combination of Rituximab, Low-Dose Cyclophosphamide, and Prednisone for Primary Membranous Nephropathy: A Case Series With Extended Follow Up.
Zonozi R; Laliberte K; Huizenga NR; Rosenthal JK; Jeyabalan A; Collins AB; Cortazar FB; Niles JL
Am J Kidney Dis; 2021 Dec; 78(6):793-803. PubMed ID: 34174365
[TBL] [Abstract][Full Text] [Related]
4. Sexual dimorphic response to rituximab treatment: A longitudinal observational study in a large cohort of patients with primary membranous nephropathy and persistent nephrotic syndrome.
Perna A; Ruggiero B; Podestà MA; Perico L; Orisio S; Debiec H; Remuzzi G; Ruggenenti P
Front Pharmacol; 2022; 13():958136. PubMed ID: 36120314
[TBL] [Abstract][Full Text] [Related]
5. Management of Membranous Nephropathy in Western Countries.
Alfaadhel T; Cattran D
Kidney Dis (Basel); 2015 Sep; 1(2):126-37. PubMed ID: 27536673
[TBL] [Abstract][Full Text] [Related]
6. Treatment of membranous nephropathy: time for a paradigm shift.
Ruggenenti P; Fervenza FC; Remuzzi G
Nat Rev Nephrol; 2017 Sep; 13(9):563-579. PubMed ID: 28669992
[TBL] [Abstract][Full Text] [Related]
7. Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome.
von Groote TC; Williams G; Au EH; Chen Y; Mathew AT; Hodson EM; Tunnicliffe DJ
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD004293. PubMed ID: 34778952
[TBL] [Abstract][Full Text] [Related]
8. Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach.
Wang S; Deng Z; Wang Y; Bao W; Zhou S; Cui Z; Zheng D
BMC Nephrol; 2023 May; 24(1):146. PubMed ID: 37237260
[TBL] [Abstract][Full Text] [Related]
9. Management of Membranous Nephropathy in Asia.
Xu J; Hu X; Xie J; Chen N
Kidney Dis (Basel); 2015 Sep; 1(2):119-25. PubMed ID: 27536672
[TBL] [Abstract][Full Text] [Related]
10. Membranous nephropathy.
Ronco P; Beck L; Debiec H; Fervenza FC; Hou FF; Jha V; Sethi S; Tong A; Vivarelli M; Wetzels J
Nat Rev Dis Primers; 2021 Sep; 7(1):69. PubMed ID: 34593809
[TBL] [Abstract][Full Text] [Related]
11. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome.
Chen Y; Schieppati A; Chen X; Cai G; Zamora J; Giuliano GA; Braun N; Perna A
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD004293. PubMed ID: 25318831
[TBL] [Abstract][Full Text] [Related]
12. Treatment resistant M-type phospholipase A2 receptor associated membranous nephropathy responds to obinutuzumab: a report of two cases.
Hudson R; Rawlings C; Mon SY; Jefferis J; John GT
BMC Nephrol; 2022 Apr; 23(1):134. PubMed ID: 35392837
[TBL] [Abstract][Full Text] [Related]
13. Membranous Nephropathy: It Is Time to Go Back to the Future.
Sabiu G; Podestà MA
Nephron; 2021; 145(6):721-727. PubMed ID: 34225270
[TBL] [Abstract][Full Text] [Related]
14. Rituximab versus steroids and cyclophosphamide for the treatment of primary membranous nephropathy: protocol of a pilot randomised controlled trial.
Scolari F; Dallera N; Gesualdo L; Santoro D; Pani A; Santostefano M; Feriozzi S; Mani LY; Boscutti G; Messa P; Magistroni R; Quaglia M; Ponticelli C; Ravani P
BMJ Open; 2019 Dec; 9(12):e029232. PubMed ID: 31806605
[TBL] [Abstract][Full Text] [Related]
15. [Membranous nephropathy: New insights in therapeutic approach].
Dahan K
Nephrol Ther; 2017 Apr; 13 Suppl 1():S83-S87. PubMed ID: 28577748
[TBL] [Abstract][Full Text] [Related]
16. Rituximab in patients with membranous nephropathy and kidney insufficiency.
Guo Y; Wang L; Wang Y; Li X; Zhai Z; Yu L; Liang Y; Liu P; Tang L
Front Pharmacol; 2022; 13():1002117. PubMed ID: 36299887
[No Abstract] [Full Text] [Related]
17. Is There a Place for Apheresis in the Management of Idiopathic Membranous Nephropathy? A Report of Three Cases and Literature Review.
Naciri Bennani H; Banza AT; Giovannini D; Motte L; Noble J; Corbu A; Malvezzi P; Jouve T; Rostaing L
J Pers Med; 2024 Feb; 14(3):. PubMed ID: 38540991
[TBL] [Abstract][Full Text] [Related]
18. Accelerating the Depletion of Circulating Anti-Phospholipase A2 Receptor Antibodies in Patients with Severe Membranous Nephropathy: Preliminary Findings with Double Filtration Plasmapheresis and Ofatumumab.
Podestà MA; Gennarini A; Portalupi V; Rota S; Alessio MG; Remuzzi G; Ruggenenti P
Nephron; 2020; 144(1):30-35. PubMed ID: 31336376
[TBL] [Abstract][Full Text] [Related]
19. [Modern view on treatment of membranous nephropathy].
Bobkova IN; Kamyshova ES
Ter Arkh; 2020 Jul; 92(6):99-104. PubMed ID: 33346502
[TBL] [Abstract][Full Text] [Related]
20. Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.
Ruggenenti P; Debiec H; Ruggiero B; Chianca A; Pellé T; Gaspari F; Suardi F; Gagliardini E; Orisio S; Benigni A; Ronco P; Remuzzi G
J Am Soc Nephrol; 2015 Oct; 26(10):2545-58. PubMed ID: 25804280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
